Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.81 |
| ▸ | FNTB | P49356 | 7/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293521 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL4293520 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL11947158 | 0.94 | FNTA (0.70) | FNTAFNTBCYP3A4 | |
| SCHEMBL13573613 | 0.92 | FNTA (0.81) | FNTAFNTBCYP3A4 | |
| SCHEMBL11955330 | 0.92 | FNTA (0.67) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954244 | 0.92 | FNTA (0.67) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954243 | 0.92 | FNTA (0.67) | FNTAFNTBCYP3A4 | |
| SCHEMBL11954824 | 0.91 | FNTA (0.66) | FNTAFNTB | |
| SCHEMBL5733786 | 0.89 | FNTA (1.00) | FNTAFNTBCYP3A4 | |
| SCHEMBL13186537 | 0.89 | FNTA (1.00) | FNTAFNTBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | FNTA 4/4885FNTB 19/4885CYP3A4 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.